Both shelves are now live, meaning selling stockholders and the company can immediately sell shares. Expect continued downward pressure as the market absorbs the massive overhang. Monitor for any takedown announcements or ATM sales; the Q2 2026 earnings report will be critical for cash runway updates.
Price Chart
Executive Summary
Two S-3 shelf registrations for Jade Biosciences became effective on May 15, 2026. File No. 333-295662 covers a resale of up to 39.5M shares by selling stockholders (57.9% of outstanding, no proceeds to company), and File No. 333-295665 covers a $600M universal shelf including a $200M ATM equity offering. Both shelves are now live, enabling immediate share sales and creating significant dilution overhang.
Key Facts
- Two S-3 shelf registrations became effective on May 15, 2026.
- File No. 333-295662: resale of up to 39.5M shares by selling stockholders (57.9% of outstanding); company receives no proceeds.
- File No. 333-295665: $600M universal shelf including a $200M at-the-market (ATM) equity offering via Jefferies.
- Effectiveness follows a Q1 2026 earnings miss (EPS -$0.57 vs -$0.52 consensus) and widened net loss of $40.4M.
- The ATM could dilute existing shareholders by up to ~16% at current prices.
- Company is pre-revenue with no near-term revenue prospects, burning cash.
Financial Impact
Potential dilution of up to 57.9% from resale shelf plus up to ~16% from ATM, totaling potentially >70% dilution overhang on a $1.2B market cap.
Risk Factors
- Immediate dilution risk from resale of 39.5M shares by insiders and large holders.
- ATM program allows company to sell up to $200M in shares, further diluting existing holders.
- Pre-revenue biotech with widening losses and no near-term revenue catalysts.
- Potential for a death spiral if cash burn accelerates and ATM is used aggressively.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (JBIO) — Batch item 1 | 9999999995-26-001671 |
| Document: 9999999995-26-001671-index.html | 9999999995-26-001672 |
| Document: 9999999995-26-001671.txt | 9999999995-26-001671 |
| EFFECT Filing (JBIO) — Batch item 4 | 9999999995-26-001672 |
| Document: 9999999995-26-001672-index.html | 9999999995-26-001671 |
| Document: 9999999995-26-001672.txt | 9999999995-26-001671 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | 8-K | $14.05 $13.77 | ▼ −1.99% | ▼ −3.91% | $14.50 (+3.20%) |
Aug 10, 2026 11w ago | 8-K | $21.73 $23.45 | ▲ +7.92% | ▲ +7.96% | $14.50 (−33.27%) |
Aug 10, 2026 11w ago | Press Release | $21.73 $23.45 | ▲ +7.92% | ▲ +7.96% | $14.50 (−33.27%) |
Jun 5, 2026 20w ago | Press Release | $14.98 $16.10 | ▼ −7.48% | ▼ −5.37% | $14.50 (+3.20%) |
Jun 4, 2026 20w ago | 8-K | $16.94 $15.34 | ▲ +9.45% | ▲ +10.01% | $14.50 (+14.40%) |
Jun 4, 2026 20w ago | 424B5 | $16.94 $15.34 | ▲ +9.45% | ▲ +10.01% | $14.50 (+14.40%) |
Jun 3, 2026 20w ago | Press Release | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 3, 2026 20w ago | 424B5 | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 3, 2026 20w ago | Press Release | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 1, 2026 21w ago | 8-K | $18.59 $16.94 | ▼ −8.88% | ▼ −6.13% | $14.50 (−22.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers